• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India.印度北部异基因造血细胞移植幸存者对长期随访预防措施的依从性。
Blood Cell Ther. 2022 Jun 10;5(3):83-86. doi: 10.31547/bct-2021-025. eCollection 2022 Aug 25.
2
Current Status and Needs of Long-Term Follow-Up Clinics for Hematopoietic Cell Transplantation Survivors: Results of a Nationwide Survey in Japan.造血干细胞移植受者长期随访门诊的现状和需求:日本全国调查结果。
Biol Blood Marrow Transplant. 2020 May;26(5):949-955. doi: 10.1016/j.bbmt.2020.01.008. Epub 2020 Jan 18.
3
Primary Preventive Care of Hematopoietic Stem Cell Transplantation Survivors: Time to Educate and Empower Recipients and Providers.造血干细胞移植受者的初级预防保健:是时候对受者和提供者进行教育和赋权了。
Transplant Cell Ther. 2023 Feb;29(2):131.e1-131.e6. doi: 10.1016/j.jtct.2022.10.028. Epub 2022 Nov 4.
4
Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors.造血细胞移植幸存者长期随访诊所推荐筛查的可行性和实用性。
Support Care Cancer. 2022 Mar;30(3):2767-2776. doi: 10.1007/s00520-021-06698-5. Epub 2021 Nov 27.
5
ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.ASBMT 实践指南委员会关于造血细胞移植存活者长期随访诊所的调查。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1119-1124. doi: 10.1016/j.bbmt.2018.03.023. Epub 2018 Mar 30.
6
[Survivorship and long-term follow-up after allogeneic hematopoietic stem cell transplantation].[异基因造血干细胞移植后的生存及长期随访]
Rinsho Ketsueki. 2021;62(6):610-618. doi: 10.11406/rinketsu.62.610.
7
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后重返工作的幸存者中复发性病假的发生率和预测因素。
J Cancer Surviv. 2023 Jun;17(3):781-794. doi: 10.1007/s11764-022-01250-8. Epub 2022 Sep 1.
8
High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后青少年和年轻成人幸存者后续随访终止的可能性较高。
Blood Adv. 2019 Feb 12;3(3):397-405. doi: 10.1182/bloodadvances.2018026039.
9
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.异基因造血细胞移植后髓系恶性肿瘤复发的第二次异基因造血细胞移植结果:代表西班牙造血移植小组的一项回顾性队列研究
Biol Blood Marrow Transplant. 2016 Mar;22(3):584-8. doi: 10.1016/j.bbmt.2015.11.012. Epub 2015 Nov 26.
10
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤患者异基因造血细胞移植的长期预后
Transplant Cell Ther. 2023 Apr;29(4):264.e1-264.e9. doi: 10.1016/j.jtct.2022.05.023. Epub 2022 May 20.

引用本文的文献

1
Factors Impacting Return to Work/School among Hematopoietic Cell Transplantation Survivors in India.影响印度造血细胞移植幸存者重返工作/学校的因素
Blood Cell Ther. 2023 Nov 3;6(4):124-128. doi: 10.31547/bct-2023-017. eCollection 2023 Nov 25.

本文引用的文献

1
Early bone loss in Indian patients undergoing allogeneic hematopoietic cell transplantation.接受异基因造血细胞移植的印度患者的早期骨质流失
Blood Cell Ther. 2021 Aug 25;4(3):48-53. doi: 10.31547/bct-2020-019.
2
Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors.造血细胞移植幸存者长期随访诊所推荐筛查的可行性和实用性。
Support Care Cancer. 2022 Mar;30(3):2767-2776. doi: 10.1007/s00520-021-06698-5. Epub 2021 Nov 27.
3
Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.成人造血细胞移植(HCT)后代谢综合征与心血管疾病:EBMT 横断面非干预性研究。
Bone Marrow Transplant. 2021 Nov;56(11):2820-2825. doi: 10.1038/s41409-021-01414-7. Epub 2021 Jul 17.
4
Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond.全球血液和骨髓移植网络建立造血细胞移植项目的建议,第一部分:最低要求及以上。
Biol Blood Marrow Transplant. 2019 Dec;25(12):2322-2329. doi: 10.1016/j.bbmt.2019.05.002. Epub 2019 May 6.
5
Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association.美国南亚裔人群的动脉粥样硬化性心血管疾病:流行病学、风险因素和治疗:美国心脏协会的科学声明。
Circulation. 2018 Jul 3;138(1):e1-e34. doi: 10.1161/CIR.0000000000000580. Epub 2018 May 24.
6
ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.ASBMT 实践指南委员会关于造血细胞移植存活者长期随访诊所的调查。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1119-1124. doi: 10.1016/j.bbmt.2018.03.023. Epub 2018 Mar 30.
7
Post stem cell transplantation revaccination: A survey of the current practices in India.干细胞移植后再接种疫苗:印度当前实践情况调查。
Vaccine. 2018 Apr 12;36(16):2176-2180. doi: 10.1016/j.vaccine.2018.02.084. Epub 2018 Mar 9.
8
The Asia-Pacific Regional Audit-Epidemiology, Costs, and Burden of Osteoporosis in India 2013: A report of International Osteoporosis Foundation.《2013年印度骨质疏松症的亚太地区审计、流行病学、成本及负担:国际骨质疏松症基金会报告》
Indian J Endocrinol Metab. 2014 Jul;18(4):449-54. doi: 10.4103/2230-8210.137485.
9
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.造血细胞移植后长期生存者的推荐筛查和预防措施。
Bone Marrow Transplant. 2012 Mar;47(3):337-41. doi: 10.1038/bmt.2012.5.
10
Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors.与造血干细胞移植存活者遵行预防保健实践相关的因素。
Biol Blood Marrow Transplant. 2011 Jul;17(7):995-1003. doi: 10.1016/j.bbmt.2010.10.023. Epub 2010 Dec 8.

印度北部异基因造血细胞移植幸存者对长期随访预防措施的依从性。

Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India.

作者信息

Khaire Niranjan S, Chhabra Prashant, Gupta Dikshat G, Jandial Aditya, Khadwal Alka, Kasudhan Kripa Shanker, Kaundal Shaweta, Chopra Madhu, Jain Arihant, Prakash Gaurav, Majhail Navneet S, Malhotra Pankaj, Lad Deepesh P

机构信息

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial, Nashville, USA.

出版信息

Blood Cell Ther. 2022 Jun 10;5(3):83-86. doi: 10.31547/bct-2021-025. eCollection 2022 Aug 25.

DOI:10.31547/bct-2021-025
PMID:36712553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9873420/
Abstract

INTRODUCTION

There are existing international guidelines for long-term follow-up (LTFU) care of allogeneic hematopoietic cell transplantation (allo-HCT) survivors. However, implementing these guidelines represents a unique challenge in resource-challenged settings.

METHODS

This study aimed to evaluate adherence to recommended surveillance in allo-HCT survivors at an academic center in North India and study the incidence of late effects. This single-center, retrospective study analyzed records of allo-HCT recipients from 2016 to 2020. Survivors were screened in our LTFU clinic at day +100 and +365 using cardiometabolic parameters (screening for hypertension, dyslipidemia, hyperglycemia, 24-hour urine protein, thyroid function), pulmonary function test (PFT), bone mineral density (BMD), and initiation of revaccination.

RESULTS

A total of 40/80 (50%) allo-HCT survivors were alive at a median of 888 days (IQR 515-1,306). The adherence to home-based screening parameters such as blood pressure and blood glucose was highest (>75%), followed by lab-based parameters (45-70%), and lowest for specialized tests such as PFT (<50%) at both day +100 and +365 time points. Adherence to the initiation of revaccination was only 67%. At least one cardiometabolic parameter was out of range in 55% and 63% of survivors at day +100 and +365, respectively.

CONCLUSION

The adherence to recommended surveillance measures for allo-HCT survivors in an academic LTFU clinic at one year was only 75% overall. Cardiometabolic abnormalities were noted in more than half of the survivors. This study emphasizes the need for a structured LTFU clinic in all centers performing HCT.

摘要

引言

对于异基因造血细胞移植(allo-HCT)幸存者的长期随访(LTFU)护理,已有国际指南。然而,在资源匮乏的环境中实施这些指南面临独特挑战。

方法

本研究旨在评估印度北部一家学术中心对allo-HCT幸存者推荐监测的依从性,并研究晚期效应的发生率。这项单中心回顾性研究分析了2016年至2020年allo-HCT受者的记录。在我们的LTFU诊所,于+100天和+365天使用心脏代谢参数(筛查高血压、血脂异常、高血糖、24小时尿蛋白、甲状腺功能)、肺功能测试(PFT)、骨密度(BMD)以及重新接种疫苗的起始情况对幸存者进行筛查。

结果

共有40/80(50%)的allo-HCT幸存者存活,中位生存期为888天(四分位间距515 - 1306天)。在+100天和+365天这两个时间点,对基于家庭的筛查参数(如血压和血糖)的依从性最高(>75%),其次是基于实验室的参数(45 - 70%),而对于诸如PFT等专门测试的依从性最低(<50%)。重新接种疫苗起始的依从性仅为67%。在+100天和+365天,分别有55%和63%的幸存者至少有一项心脏代谢参数超出范围。

结论

在一家学术性LTFU诊所,allo-HCT幸存者对推荐监测措施的一年总体依从性仅为75%。超过一半的幸存者存在心脏代谢异常。本研究强调在所有进行HCT的中心都需要一个结构化的LTFU诊所。